公开(公告)号：US20190083637A1

公开(公告)日：2019-03-21

申请号：US15925830

申请日：2018-03-20

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Ick Chan KWON ,  Juho PARK

IPC: A61K47/64 ,  A61K47/69 ,  A61K31/704 ,  A61K9/51

Abstract: Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.

公开(公告)号：US20200071698A1

公开(公告)日：2020-03-05

申请号：US16425849

申请日：2019-05-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Sun Hwa KIM ,  Ick Chan KWON ,  Kwangmeyung KIM ,  Hong Yeol YOON ,  Gi-Jung KWAK ,  Juho PARK

IPC: C12N15/113 ,  A61P35/00

Abstract: The present invention relates to a novel anti-miRNA single-stranded nucleic acid maleimide derivative, which comprises an anti-miRNA single-stranded nucleic acid having a nucleic acid sequence complementary to a nucleic acid sequence of an miRNA. Further, the present invention provides an anti-miRNA single-stranded nucleic acid-serum albumin conjugate in which serum albumin is covalently bonded to the anti-miRNA single-stranded nucleic acid maleimide derivative via the maleimide group.